Radiosensitization of IDH-Mutated Gliomas through ZMYND8 – a Pathway to Improved Outcomes Available to Purchase

Isocitrate dehydrogenase 1–mutant (IDH1m) gliomas are recalcitrant tumors for which radiotherapy remains a standard treatment. A recent study identified ZMYND8 as a key mediator of radioresistance for IDH1m gliomas, and pharmacologic targeting of this pathway may heighten radiotherapy-induced tumor response, providing a prospect of improved clinical outcomes.

See related article by Carney et al., p. 1763